Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Abstract 5998: In vitro and in vivo anticancer effects of D/L-alpha-metyrosine (SM-88), a novel metabolism-based therapy
Vandell, Alexander G., Eckard, Jonathan, Hoffman, Steve, Priore, Giuseppe Del, Fernández-Zapico, Martín E.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 5998-5998

10.1158/1538-7445.am2020-5998 Get It

Abstract Introduction: D/L-alpha-metyrosine (SM-88, racemetyrosine) is a clinical stage chemically modified racemic amino acid therapy with broad anticancer activity in patients across 15 different indications. While amino acid metabolism has been leveraged in oncology imaging for decades, SM-88 offers a novel therapeutic approach to selectively disrupt cancer cells. This study explored phenotypic and mechanistic effects of exposing cancer cells to D/L-alpha-metyrosine as well as potential immunomodulation of the in vivo tumor microenvironment related to tyrosine hydroxylase inhibition and catecholamine depletion. Methods: In vitro experiments were conducted in a range of human and mouse cancer cell lines, including MCF-7, 4T1, HCT116, CAPAN2, PAN02, PANC01. The effect of SM-88 methyl-ester (SM-88 ME) alone on viability, apoptosis, migration/invasion, protein synthesis inhibition, autophagy, cell cycle arrest, and ROS generation was assessed. In vivo experiments included xenograph studies of HCT116 with monotherapy consisting of either IP injections up to 200 mg/kg/day of SM-88 ME, or orally administered SM-88 up to 324 mg/kg/day. Orthotopic xenographs of 4T1 and PAN02 models using monotherapy doses up to 200 mg/kg/day are ongoing. Ongoing immunohistochemistry and flow cytometry is focused on correlation with LAT1 expression and efficacy, alteration in macrophage polarization (M1/M2 ratio), Tregs, and various T cell populations in the tumor microenvironment. Results: Exposure to SM-88 ME exhibited a dose dependent increase in ROS, as well as decreases in caspase 3/7 activation. An increase in ROS following exposure to SM-88 ME was also observed in PAN02 cells. Similar decreases in caspase 3/7 activation were observed in CAPAN2, HCT116, and MCF7 cells. Interestingly, across a variety of cell lines including PAN02, PANC1, and 4T1 cell morphology changes suggested the formation of autophagic vacuoles. Viability across all cell lines was reduced in a dose and time dependent manner. In a mouse HCT116 SC xenograft model, mice receiving 324 mg/kg/day SM-88 ME showed significantly reduced tumor size compared to control mice. Additional in vitro and in vivo experiments are ongoing. Conclusions: The importance of amino acid metabolism in cancer has gained greater awareness over the past decade, however potential therapeutic approaches in this area remain limited. SM-88 has been dosed in over 180 cancer patients with encouraging efficacy and safety findings to date. Early data suggest increases in ROS generation and decreases in apoptosis may occur in certain cancer types (PAN02 pancreatic cancer), suggesting a shift away from apoptosis and towards autophagy. Potential immune modulatory effects of SM-88, including alterations in macrophage polarization related to tyrosine hydroxylase inhibition and subsequent reductions in catecholamine production are being examined. Citation Format: Alexander Vandell, Jonathan Eckard, Steve Hoffman, Giuseppe Del Priore, Martin Fernandez-Zapico. In vitro and in vivo anticancer effects of D/L-alpha-metyrosine (SM-88), a novel metabolism-based therapy [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5998.
Abstract 5622: scRNA-seq reveals restructuring of the immune microenvironment of multiple myeloma following treatment with an IAP antagonist
Welsh, Seth J. , Garbitt, Victoria M. , Chesi, Marta , Stein, Caleb K. , Meermeier, Erin W. , Sharik, Meaghen E. , Bergsagel, P. Leif , Banovich, Nicholas E. , Keats, Jonathan J.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 5622-5622

10.1158/1538-7445.am2020-5622 Get It

Abstract Previously, the IAP antagonist LCL161 was shown to have robust anti-myeloma activity in a transgenic mouse model where an acute inflammatory response accompanied a reduction in tumor burden. In order to fully examine alterations to the immune microenvironment, murine splenocytes from twenty mice transplanted with Vk12598 myeloma and administered single-agent treatment regimens of LCL161, cyclophosphamide, or bortezomib were harvested after 24 hours and subjected to single cell RNA-seq sequencing. After initial removal of erythrocytic and mitochondrial expressing cells, count matrices of over 50,000 total cells span twenty murine whole spleen samples. In an examination of the myeloid component, we identified 13 clusters of immune cells with unique compositions across samples due to differing treatment regimens and initial tumor burden. While minimally present in all seven non-transplanted mice, macrophages with elevated expression of complement activation system genes (C1q) were the most abundant myeloid cell population in each of our untreated, Vk12598 transplanted mice. Alternatively, populations of cDC2, pDC, moDC, and monocytes lacking expression of MHC class II markers were fixtures for healthy controls while markedly less abundant in tumor-bearing mice. Tumor burdens in three samples subjected to LCL161 therapy were significantly reduced 24-hours post treatment and accompanied by an expansion of late-stage neutrophils and migratory DCs with expression features mirroring those of DCs from mesenteric lymph nodes. This composition of immune cells was distinct from all other sample including those treated with cyclophosphamide or bortezomib. In addition, relative proportions of B, T, and NK cells were nearly fully reconstituted, matching levels observed in healthy controls, in two of these samples. In a direct functional assessment, expression levels of Fscn1 and Ccr7 (key over-expressed genes in these migratory DCs) markedly increased following treatment of bone marrow derived DCs with LCL161. Overall, the transcriptional profile of these migratory DCs indicates their pivotal role in maturation of DCs (Fscn1, Tmem123) as well as the recruitment of T and NKT cells (Cxcl16, Ccr7) and increase in antigen presentation (Cd63)–all of which may serve to ‘warm' tumors, increasing T cell infiltration necessary for immunotherapy approaches. With the increased resolution of scRNA-seq, we observe unique alterations in the composition of the immune microenvironment of MM induced by treatment with LCL161 that further detail its unique mechanism of anti-MM activity. Citation Format: Caleb K. Stein, Erin Meermeier, Seth Welsh, Victoria Garbitt, Meaghen Sharik, P. Leif Bergsagel, Nicholas Banovich, Jonathan Keats, Marta Chesi. scRNA-seq reveals restructuring of the immune microenvironment of multiple myeloma following treatment with an IAP antagonist [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5622.
Abstract 2764: In vivo mouse model data demonstrating reduction in tumor cell proliferation following intratumoral administration of TYME 18
Rothman, John, Hoffman, Steve, Ocean, Allyson J. , Eckard, Jonathan, Priore, Giuseppe Del, Fernández-Zapico, Martín E.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 2764-2764

10.1158/1538-7445.am2020-2764 Get It

Abstract Introduction: TYME-18 is a combination of an ambiphilic steroid acid, tauroursodeoxycholic acid (TUDCA) and surfactants (N-methyl pyrrolidone, polidocanol, and linoleic acid) administered intratumorally to induce regression without injuring adjacent tissue. Methods: Balb/C mice were inoculated with CT-26 cancer (106 cells) until a tumor was established to approximately 100 mm3. An initial feasibility semi-quantitative assessment was performed with 10 animals (table 1). A larger confirmatory experiment testing the individual components of TYME-18 was also conducted (tables 2 & 3). Mice received intra-tumoral injections of TYME-18 with surfactants; or surfactants without TUDCA, or vehicle with measurements 3 times/wk. Intra-tumoral injections were administered 6 times at 3-day intervals over a total of 4 weeks. Animals were sacrificed when tumors reached 2000 mm3 or at the end of the study (16 weeks). Table 1.HISTOPATHOLOGIC FINDINGSFinal tumor sizes & intratumoral necrosis. TYME-18 vs Control. CT-26 model. (Fisher's Exact Test p=0.001)GroupAnimal IDTumor SizeIntratumoral NecrosisControlG1A-1>1 cmModerateG1A-2>1 cmMildG1B-2>1 cmMildG1B-3>1 cmModerateG1B-4>1 cmModerate-TreatedG2A-1<1 – 5 mmSevereG2A-3<1 – 5 mmSevereG2B-1<1 – 5 mmSevereG2B-3<1 – 5 mmSevereG2B-55 – 6 mmSevere- Table 2.Days Post Implementation average tumor volume mm3 (ANOVA P<0.0001)0369121520Vehicle83.1157.9263.4401.4613.9849.41368.9Surfactant Alone76.4131.1166.3209.6274.3345.7642.8TYME-1880.528.228.934.235.854.457.2- Table 3.Tumor Free Mice at Study End: Day 112 (Fisher's Exact Test p < 0.0001)Treatment# of Mice# Tumor Free Mice% Tumor Free MiceVehicle2000Surfactant Alone1218.33TYME-18121191.6 Results: TYME-18 demonstrated a significant difference between treated and untreated animals (see Tables 1, 2, 3). A minor reduction in tumor cell mass was observed in response to the surfactant, with the greatest response (ANOVA p=.001) observed in the TYME-18 (surfactant + TUDCA) (table 2). Discussion: The local administration of an ambiphilic steroid acid along with surfactants, impeded the ability of tumors to increase in size. Both the surfactants and the ambiphilc steroid acid contributed to this effect with an apparent synergistic effect. Aside from the physical chemical acid effect on tissue, ambiphilic steroid acids are now recognized as important regulators of energy metabolism. Their effects on FXR, LXR, PPAR-α, PPAR-γ are known to regulate important changes in energy metabolism including insulin utilization, the sensitivity of the insulin receptor, the transcription of the genes that mediate glucose and lipid metabolism as well as various immune effects; all of which could be useful in the treatment of cancer. Currently, TYME-18 is under investigation as a simple and nontoxic treatment for tumors for which systemic therapy is not indicated. Citation Format: John Rothman, Steve Hoffman, Allyson Ocean, Jonathan Eckard, Giuseppe Del Priore, Martin Fernandez-Zapico. In vivo mouse model data demonstrating reduction in tumor cell proliferation following intratumoral administration of TYME 18 [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2764.
Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes
Ighodaro, Eseosa T. , Graff‐Radford, Jonathan , Syrjanen, Jeremy A. , Bui, Hai H., Petersen, Ronald C. , Knopman, David S. , Jack, Clifford R. , Zuk, Samantha M., Vemuri, Prashanthi , Mielke, Michelle M. , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Syrjanen, Jeremy A

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | September 3, 2020 | Volume: 40 | Issue: 11 | Pages: 2785-2793

10.1161/atvbaha.120.314796 | PMID 32878474 Get It

Objective: High plasma ceramide levels and ratios are associated with poor outcomes in individuals with cardiovascular disease; less is known about their relation to cerebral small vessel disease. We examined whether high plasma ceramide levels or ratios were associated with cerebral microbleeds (CMBs) and lacunes and whether associations differ by sex. Approach and Results: We included 548 participants enrolled in the MCSA (Mayo Clinic Study of Aging) with concurrent plasma ceramide assays and magnetic resonance imaging. CMBs were quantified on T2* magnetic resonance imaging and lacunes on T2 fluid-attenuated inversion recovery magnetic resonance imaging. Fasting plasma ceramides were assayed using liquid chromatography-electrospray ionization tandem mass spectrometry. We used logistic regression models adjusting for age, sex, hypertension, and diabetes mellitus to examine the relationship between ceramides and presence of a lacune; hurdle models were used for presence and number of CMBs. Each SD increase in the log ceramide C16:0/24:0 ratio was associated with greater odds of a CMB (odds ratio, 1.28 [95% CI, 1.01–1.64]). There was an interaction between sex and the ceramide C16:0/24:0 ratio ( P =0.049). The association between this ratio and presence of a CMB was stronger for women (odds ratio, 1.87 [95% CI, 1.20–3.00]) than men (odds ratio, 1.09 [95% CI, 0.80–1.46]). Several ceramides and all ceramide ratios were associated with number of CMBs. We did not find associations between plasma ceramides and lacunes. Conclusions: In a population-based sample, the plasma ceramide C16:0/24:0 ratio was associated with CMBs and was stronger for women. Plasma ceramides are differentially associated with cerebral small vessel pathologies.
Targeted Metagenomics for Clinical Detection and Discovery of Bacterial Tick-Borne Pathogens
Kingry, Luke C. , Sheldon, Sarah W., Oatman, Stephanie, Pritt, Bobbi S. , Anacker, Melissa , Bjork, Jenna , Neitzel, David F., Strain, Anna K., Berry, Jon, Sloan, Lynne M., Respicio-Kingry, Laurel, Dietrich, Elizabeth A. , Bloch, Karen C. , Moncayo, Abelardo C., Srinivasamoorthy, Ganesh, Hu, Bin , Mead, Paul S. , Petersen, Jeannine M., Kingry, Luke , Pritt, Bobbi, Sloan, Lynne, Pritt, Bobbi S , Berry, Jonathan, Hinckley, Alison F. , Kugeler, Kiersten J.

Mayo Clinic

Journal of Clinical Microbiology | September 1, 2020 | Volume: 58 | Issue: 11 | Pages: No page available

10.1128/jcm.00147-20 | PMID 32878950 Get It

Tick-borne diseases, due to a diversity of bacterial pathogens, represent a significant and increasing public health threat throughout the Northern Hemisphere. A high-throughput 16S V1-V2 rRNA gene-based metagenomics assay was developed and evaluated using >13,000 residual samples from patients suspected of having tick-borne illness and >1,000 controls. Taxonomic predictions for tick-borne bacteria were exceptionally accurate, as independently validated by secondary testing. Overall, 881 specimens were positive for bacterial tick-borne agents.
Demystifying the Deep Plane Facelift: What It Means Anatomically and Why It Works
Sykes, Jonathan M., Dilger, Amanda E. , Sykes, Jonathan , Cotofana, Sebastian

Mayo Clinic

Facial Plastic Surgery | August 31, 2020 | Volume: 36 | Issue: 04 | Pages: 351-357

10.1055/s-0040-1714267 | PMID 32866973 Get It

AbstractRhytidectomy is a common procedure performed by facial plastic surgeons. On well-selected patients, rhytidectomy rejuvenates the aging face by repositioning soft tissues and improving facial shape. The fundamental goal of rhytidectomy, or facelift surgery, is to provide a more youthful facial appearance by elevating soft tissues that often descend with aging. The success and longevity of any rhytidectomy procedure are based on the individual patient's anatomy and aging and on the mobilization, elevation, and fixation of the soft tissues during the facelift procedure. Although surgeons often use many terms to describe a given facelift technique, anatomical terms are best used to name the facelift procedure, as the plane of dissection and the vector of elevation are what determines the end result. This paper attempts to simplify and demystify the deep plane facelift procedure and to describe the anatomy that makes this technique successful.
Teaching Points: Overview of Spinal Cord Stimulation Lead Migration
Esomonu, Chiamaka, Hagedorn, Jonathan M. , Hagedorn, Jonathan M

Mayo Clinic

Pain Medicine | August 28, 2020 | Volume: 22 | Issue: 2 | Pages: 520-522

10.1093/pm/pnaa328 | PMID 33155048 Get It

Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study
Okonkwo, David O. , Puffer, Ross C. , Puccio, Ava M. , Yuh, Esther L. , Yue, John K. , Korley, Frederick K. , Sun, Xiaoying, Taylor, Sabrina R. , Jain, Sonia , Manley, Geoffrey T. , Boase, Kim, Bullock, Ross, Crawford, Karen , Dikmen, Sureyya, Duhaime, Ann-Christine, Ellenbogen, Richard G. , Feeser, V. Ramana, Ferguson, Adam R. , González, Luis, Gopinath, Shankar P. , Gullapalli, Rao P. , Hemphill, Claude, Hotz, Gillian , Kramer, Joel H. , Kreitzer, Natalie , Levin, Harvey S. , Machamer, Joan , Madden, Christopher , McAllister, Thomas W. , McCrea, Michael , Merchant, Randall E., Noël, Florence, Palacios, Eva , Perl, Daniel P. , Rabinowitz, Miri, Robertson, Claudia S. , Satris, Gabriella, Seabury, Seth A., Sherer, Mark , Stein, Murray , Temkin, Nancy, Toga, Arthur W. , Valadka, Alex B. , Vassar, Mary J. , Vespa, Paul , Zafonte, Ross , Diaz‐Arrastia, Ramon , Wang, Kevin , Mukherjee, Pratik , Markowitz, Amy J. , Adeoye, Opeolu M , Badjatia, Neeraj , Bodien, Yelena G. , Chesnut, Randall Matthew , Corrigan, John D. , Foreman, Brandon , Gardner, Raquel C. , Gaudette, Étienne , Giacino, Joseph T. , Goldman, Dana P. , Lindsell, Christopher J. , Martin, Alastair J. , Nelson, Lindsay D. , Ngwenya, Laura Benjamin , Rosand, Jonathan M. , Sander, Angelle M. , Schnyer, David M. , Stein, Murray B.

Mayo Clinic

Journal of Neurotrauma | August 28, 2020 | Volume: 37 | Issue: 23 | Pages: 2460-2467

10.1089/neu.2020.7140 | PMID 32854584 Get It

Glial fibrillary acidic protein (GFAP) is cleared by the Food and Drug Administration (FDA) to determine need for head computed tomography (CT) within 12 h after mild traumatic brain injury (TBI) (Glasgow Coma Score [GCS] 13–15); S100 calcium-binding protein B (S100B) serves this function in Europe. This phase 1 biomarker cohort analysis of the multi-center, observational Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study compares GFAP's diagnostic performance, measured on a rapid point-of-care platform, against protein S100B to predict intracranial abnormalities on CT within 24 h post-injury across the spectrum of TBI (GCS 3–15). Head CT scan performed in TBI subjects and blood was collected for all consenting subjects presenting to 18 United States level 1 trauma centers. Plasma was analyzed on a point-of-care device prototype assay for GFAP and serum was analyzed for S100B. In 1359 patients with TBI (GCS 3–15), mean (standard deviation [SD]) age = 40.1 (17.0) years; 68% were male. Plasma GFAP levels were significantly higher in CT+ TBI subjects (median = 1358 pg/mL, interquartile range [IQR]: 472–3803) than in CT- TBI subjects (median = 116 pg/mL, IQR: 26–397) or orthopedic trauma controls ( n = 122; median = 13 pg/mL, IQR: 7–20), p < 0.001. Serum S100B levels were likewise higher in CT+ TBI subjects (median = 0.17 μg/L, IQR: 0.09–0.38) than in CT- TBI subjects (median = 0.10 μg/L, IQR: 0.06–0.18), p < 0.001. Receiver operating characteristic curves were generated for prediction of intracranial injury on admission CT scan; area under the curve (AUC) for GFAP was significantly higher than for S100B in the same cohort (GFAP AUC – 0.85, 95% confidence interval [CI] 0.83–0.87; S100B AUC – 0.67, 95% CI 0.64-0.70; p < 0.001). GFAP, measured on a point-of-care platform prototype assay, has high discriminative ability to predict intracranial abnormalities on CT scan in patients with TBI across the full injury spectrum of GCS 3–15 through 24 h post-injury. GFAP substantially outperforms S100B.
The Surgeon’s View of the Left Ventricular Outflow Tract in Congenital Heart Surgery
Stephens, Elizabeth H. , Johnson, Jonathan N. , Ackerman, Michael J. , Ommen, Steve R. , Dearani, Joseph A. , Schaff, Hartzell V.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | August 27, 2020 | Volume: 11 | Issue: 5 | Pages: 595-610

10.1177/2150135120936632 | PMID 32853058 Get It

Left ventricular outflow tract (LVOT) obstruction is a component of many forms of congenital heart disease, including hypertrophic cardiomyopathy, membranous subaortic stenosis, tunnel subaortic stenosis, and outflow tract obstruction related to atrioventricular septal defects. We have gained a particularly extensive experience with the diagnosis and treatment of hypertrophic cardiomyopathy, having performed septal myectomy in over 3,800 patients. In the setting of this review of LVOT obstruction, we use hypertrophic cardiomyopathy as a template by which other pathologies causing LVOT obstruction can be understood. We review important surgical issues in patient selection, diagnostic evaluation, interpretation of imaging, and operative management. To this end, the review focuses on obstructive hypertrophic cardiomyopathy and then broadens to discuss other pathologies causing LVOT obstruction, with important similarities and differences in their management. These other pathologies share some similar presentations and operative techniques, and at times can be confused with hypertrophic cardiomyopathy, but also have important distinctions of which the surgeon should be aware.
Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophtha
Singer, Michael C. , Marchal, Francis, Bernet, Vic, Boucai, Laura , Buchholzer, Samanta , Burkey, Brian B., Eisele, David W. , Faure, Fréderic , Freitag, Suzanne K. , Gillespie, M. Boyd , Harrell, R. Mack, Hartl, Dana M. , Haymart, Megan R. , Leffert, Jonathan, Mandel, Susan J., Miller, Barbra S. , Pearce, Elizabeth N. , Rahmati, Rahmatullah, Ryan, William R. , Schaitkin, Barry M., Schlumberger, Martin, Stack, Brendan C. , Nostrand, Doug Van, Wong, Ka Kit , Stack, Brendan C , Pearce, Elizabeth N , Angelos, Peter , Bernet, Victor , Buchholzer, Samanta , Erkul, Evren , Morris, John, Nostrand, Douglas Van , Randolph, Gregory William

Mayo Clinic

Head & Neck | August 26, 2020 | Volume: 42 | Issue: 11 | Pages: 3446-3459

10.1002/hed.26417 | PMID 32812307 Get It

AbstractBackgroundPostoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement.MethodsA multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations.ResultsConsensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management.ConclusionSalivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.